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1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE 
COMPANY/UNDERTAKING
Product Name Rapamune Oral Solution
Common Name Not available
Chemical Name Not applicable
Synonyms Not available
Product Use Pharmaceutical product
Classification  Immunosuppresive Agent
 
Supplier Wyeth 
P.O. Box 8299 
Philadelphia, PA 19101 USA. 
Telephone: 1-610-688-4400
 
Emergency Telephone Number Chemtrec USA, Puerto Rico, Canada 1-800-424-9300 
Chemtrec International   1-703-527-3887
 
2. COMPOSITION/INFORMATION ON INGREDIENTS
 
Common Name  CAS-No EC No. Composition  Classification 
Inactive Ingredients  Not applicable Not applicable Remainder Not applicable
Sirolimus 53123-88-9 Not available 1 mg/ml Xn; R22, R36; S22, S24/25, S 36/37
Ethanol 64-17-5 200-578-6 1.5 - 2.5% R38, S37
  
3.  HAZARDS IDENTIFICATION
 
 
Potential Physical Hazards  None known
 
Potential Health Effects
 Eyes Irritating to eyes.
 Skin May cause irritation.
 Inhalation May cause mucous membrane and upper respiratory tract irritation.
 Ingestion The most common effects may include increased susceptibility to infections such as bronchitis, 
Herpes simplex, pneumonia, pyelonephritis, upper respiratory infection, urinary tract infection, 
abscess, cellulitis, Herpes zoster infection, peritonitis, sepsis, gastritis, gastroenteritis, 
gingivitis, mouth ulceration, oral moniliasis, stomatitis, cough increase, pneumoniasinusitis, 
fungal dermatitis, skin ulcer, conjunctivitis, fever, chills, arthralgia, pain, malaise, sweating, flu 
syndrome, kidney problems and exfoliative dermatitis. May inhibit production of certain growth 
factors that affect angiogenesis, fibroblast proliferation and vascular permeability; affect wound 
healing; cause fluid retention including peripheral edema, lymphedema, pleural effusion and 
pericardial effusion. 
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Emergency Overview
This contains an active pharmaceutical ingredient that can affect body functions; handle with caution. 
Safety Data Sheet 
European Format   
   
Preparation Date  03-Jul-2007  Revision Date 05-Sep-2008 
 
Revision Number 3 
 
Rapamune Oral Solution 
Odor Not available  Appearance Pharmaceutical Liquid  Physical State  Liquid _____________________________________________________________________________________________ 
 
May cause cancer. May cause harm to the unborn child. May impair fertility. The possible 
development of lymphoma may result from immunosuppression. 
Please see Patient Package Insert for further information. 
  Therapeutic Target Organ(s) Immune system.
    Not listed by OSHA, NTP or IARC. Potential cancer hazard.
 
Potential Environmental Effects See Section 12.
  
4. FIRST AID MEASURES
Eye Contact In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek 
medical advice.
Skin Contact Take off contaminated clothing and shoes immediately. Wash off immediately with soap and 
plenty of water. If skin irritation persists, call a physician.
Inhalation Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, 
call a physician.
Ingestion If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never 
give anything by mouth to an unconscious person.  
 
5. FIRE-FIGHTING MEASURES
Flammable Properties  Slightly flammable
 
Extinguishing Media 
 
  Suitable Extinguishing Media Use alcohol-resistant foam, dry chemical or carbon dioxide..
 Unsuitable  Extinguishing 
Media
Do NOT use water jet.
 
Fire Fighting Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with 
water spray. In the event of fire and/or explosion do not breathe fumes.
 
Hazardous Combustion Products  Carbon oxides, nitrogen oxides.
 
Protective Equipment and 
Precautions for Firefighters
In the event of fire, wear self-contained breathing apparatus and special protective equipment 
for fire fighters.
  
6. ACCIDENTAL RELEASE MEASURES
Personal Precautions Refer to protective measures listed in Sections 7 and 8.
 
Environmental Precautions Prevent product from entering drains. Local authorities should be advised if a significant spill 
cannot be contained.
 
Methods for Containment  Not available
 
Methods for Cleaning up Take up mechanically and collect in suitable container for disposal. Clean contaminated 
surface thoroughly. Avoid formation of dust and aerosols.
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7. HANDLING AND STORAGE
Handling For personal protection see Section 8. Handle in accordance with good industrial hygiene and 
safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols. 
 
Storage No special safety precautions required. Keep container tightly closed.
 
8. EXPOSURE CONTROLS / PERSONAL PROTECTION
 
Common Name  Exposure Guideline 
Sirolimus 1 mcg/m3
Ethanol 1900 mg/m3
 
Engineering Controls Apply technical measures to comply with the occupational exposure guideline. Enclose 
operations to prevent aerosol generation. General ventilation shall not be used as the primary 
control system. Isolators, fume hoods, or biological safety cabinets may be used based on a 
risk assessment.
Personal Protective Equipment
 Eye/face  Protection Avoid contact with skin and eyes. Provide eye protection based on risk assessment..
 Skin  Protection Wear nitrile or latex gloves. Wear protective garment.
 Respiratory  Protection Base respirator selection on a risk assessment..
 
 General  Hygiene 
Considerations
When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands 
before breaks and at the end of workday.
 
 Other  Consult a health and safety professional for specific PPE, respirator, and risk assessment 
guidance.
 
9. PHYSICAL AND CHEMICAL PROPERTIES
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Not applicable  Evaporation Rate  Not available 
Odor 
Partition Coefficient 
(n-octanol/water) 
Not available 
Not available 
Vapor Pressure  Not available 
Appearance 
Boiling Point  Not applicable 
Odor Threshold   Not available 
Autoignition Temperature  Not applicable 
Pharmaceutical Liquid 
Flash Point  Not applicable 
Revision Date Not applicable 
Melting Point  Not applicable 
Flammability Limits in Air   
pH  
Upper Not available 
Not available 
Lower Not available     
Physical State   Liquid 
Explosion Limits   
 
Upper Not applicable 
 
Lower Not applicable 
Rapamune Oral Solution 
Specific Gravity  Not available 
Color 
Water Solubility  Insoluble 
Yellow 
Solubility _____________________________________________________________________________________________ 
 
10. STABILITY AND REACTIVITY
Chemical Stability Stable at room temperature.
 
Conditions to Avoid No data available
 
Materials to Avoid No materials to be especially mentioned.
 
Hazardous Decomposition Products None under normal use.
 
Possibility of Hazardous Reactions  None under normal use.
  
11. TOXICOLOGICAL INFORMATION
 
Acute Toxicity
Multiple Dose Toxicity
Maximum Tolerated Dose (MTD), Oral
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Hypersensitivity reactions, including anaphylactic or anaphylactoid reactions have been 
reported with therapeutic use of Sirolimus. 
   No Toxicologic Effect 
Dose/Species/Study Length: 
See below 
   LD50 Oral 
Ethanol 
Ethanol 
   No Toxicologic Effect 
Dose/Species/Study Length: 
Repeated contact can dry the skin with cracking, peeling, and itching. Repeated high exposure 
may affect the liver and nervous system. 
>800 mg/kg rats
>2500 mg/kg mice
IP 600 mg/kg mice 
   LD50 Oral  3450 mg/kg mice
7060 mg/kg rats 
Rapamune Oral Solution 
Sirolimus 
   Acute Dermal Irritation 
   Carcinogenicity  Animal studies revealed increased incidences of lymphoma in mice, hepatocellular tumors in 
male mice, granulocytic leukemia in female mice, and testicular interstitial cell adenoma in rats. 
Moderate irritation effect in rabbits. 
  
   Genetic Toxicity  Negative in a battery of genotoxicity tests. 
Acute Dermal Irritation  Not available 
   Reproductive Toxicity  In all reproductive studies, embryo/fetal toxicity was manifested as decreased number of 
fetuses and/or pups and decreased fetal and/or pup weights, and resulted in maternal toxicity 
(decreased body weight parameters) in rats. 
   Primary Eye Irritation  Severely irritating to rabbit eyes. 
   Developmental Toxicity  No teratogenic effects were observed in rats or rabbits. 
Ethanol 
Sirolimus 
  
   Carcinogenicity  No data available 
Sensitization  Not applicable 
   Primary Eye Irritation  Not available 
Revision Date Not applicable 
  
Sirolimus 
Sensitization _____________________________________________________________________________________________ 
 
 
12. ECOLOGICAL INFORMATION
 
Chemical Fate Information
Ecotoxicity
 
13. DISPOSAL CONSIDERATIONS
Waste Disposal Method Dispose of in accordance with local and national regulations.
  
14. TRANSPORT INFORMATION
  
 
15. REGULATORY INFORMATION
According to present data no classification and labeling is required according to Directives 67/548/EEC or 1999/45/EC.
 
 
16. OTHER INFORMATION
Prepared By Wyeth Department of Environment, Health & Safety
Format  This MSDS was prepared in accordance with Directive 2001/58/EC.
List of References See Patient Package Insert for more information.
Revision Summary  Changes to Section 8
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Sirolimus 
    Target Organ(s) of Toxicity  No data available 
   Mobility  May adsorb on sludge or particles in natural waters. 
Reproductive Toxicity  See Developmental Toxicity. 
   Biodegradability  Not available 
Transport Information 
Ethanol 
This material is not classified as hazardous for transport. 
   Stability in Water   Hydrolyses in water. 
Rapamune Oral Solution 
   Bioaccumulation  Bioaccumulative potential. 
    Target Organ(s) of Toxicity  No data available 
   Developmental Toxicity  Repeated exposure may cause spontaneous abortions, as well as birth defects and other 
developmental problems (fetal alcohol syndrome). 
Sirolimus 
   Genetic Toxicity 
   Microorganisms  EC50 > Aqueous solubility limit 
May cause genetic changes. 
   Algae  EC50/72h/algae = 0.063 mg/l, NOEC = 0.015 mg/l 
Revision Date Not applicable 
Sirolimus 
   Daphnia  EC50/48h/daphnia > Aqueous solubility limit, NOEC > Aqueous solubility limit. 
   Fish   LC50/96h/Fathead minnows > Aqueous solubility limit, NOEC > Aqueous solubility limit. 
  _____________________________________________________________________________________________ 
 
 
Disclaimer:
The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in 
materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be 
reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, 
INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR 
ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, 
OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages 
resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible 
for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is 
suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or 
product in accordance with all appropriate and applicable regulations. This information relates only to the API or product 
designated herein, and does not relate to its use in combination with any other API, material, product, or process. No 
permission is granted for the use of any API or product in a manner that might infringe on existing patents.
 
End of MSDS 
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